Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Niels Jonas Heilskov Graversen | M | - |
Cytoguide ApS
 Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.
University of Aarhus
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.
DeLiver Pharma ApS
 DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | 22 Jahre |
| Søren Kragh Moestrup | M | - |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.
DeLiver Pharma ApS
DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | 11 Jahre |
| Jens Kristian Damsgaard | M | - |
DeLiver Pharma ApS
DeLiver Pharma ApS Pharmaceuticals: MajorHealth Technology DeLiver Pharma ApS manufactures pharmaceutical products. The firm carries on business with medical development and any related business. The company was founded on March 9, 2018 and is headquartered in Odense, Denmark. | - |
| Søren Møller | M | 56 |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | 8 Jahre |
| Lars Henrik Fugger | M | 64 |
University of Aarhus
| 28 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Henrik Andersen | M | 56 |
University of Aarhus
| 9 Jahre |
| Rune Hansen | M | - |
University of Aarhus
| 6 Jahre |
| Gian Luca Cattani | M | 55 |
University of Aarhus
| 4 Jahre |
| Martin Lippert | M | 57 |
University of Aarhus
| 5 Jahre |
| Milan Zdravkovic | M | 54 |
University of Aarhus
| 11 Jahre |
| Karsten Breum | M | 51 |
University of Aarhus
| 4 Jahre |
| Carsten Fensholt | M | 62 |
University of Aarhus
| 4 Jahre |
| Jacob Vittrup | M | 53 |
University of Aarhus
| 1 Jahre |
| Merete Vangsøe Simonsen | F | 57 |
University of Aarhus
| 3 Jahre |
| Nanna Liebach Lüneborg | M | 49 |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | - |
| Anders Lund | M | 51 |
University of Aarhus
| 4 Jahre |
| Kristian Villumsen | M | 54 |
University of Aarhus
| 1 Jahre |
| Steffen Sørensen | M | - |
University of Aarhus
| 4 Jahre |
| Erik Dudman Nielsen | M | - |
University of Aarhus
| 1 Jahre |
| Mikael Andreas Geday | M | 56 |
University of Aarhus
| 3 Jahre |
| Line Christa Amanda Sørensen | F | 49 |
University of Aarhus
| 3 Jahre |
| Jesper Ejlersen | M | 57 |
University of Aarhus
| 1 Jahre |
| Karsten Munk Knudsen | M | 53 |
University of Aarhus
| 1 Jahre |
| Ulrik Thagesen | M | 53 |
University of Aarhus
| 1 Jahre |
| Kasper Støy | M | - |
University of Aarhus
| 2 Jahre |
| Stenkil Ole | M | 51 |
University of Aarhus
| 5 Jahre |
| Dorthe Berntsen | M | 62 |
University of Aarhus
| 3 Jahre |
| Casper Blaase Johansen | M | 49 |
University of Aarhus
| 4 Jahre |
| Tina Høgsted Svanberg | F | - |
University of Aarhus
| 4 Jahre |
| Søren Elmann Ingerslev | M | - |
University of Aarhus
| 3 Jahre |
| Morten Beck Jørgensen | M | - |
University of Aarhus
| 1 Jahre |
| René Schneider | M | 51 |
University of Aarhus
| 6 Jahre |
| Theis Rauhe | M | - |
University of Aarhus
| 3 Jahre |
| Peter Buhl Jensen | M | 69 |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | 1 Jahre |
| Jørgen Jensen | M | 56 |
University of Aarhus
| 1 Jahre |
| Kristian Johnsen Hundebøll | M | 58 |
University of Aarhus
| 4 Jahre |
| Alex Haahr Gouliaev | M | 58 |
University of Aarhus
| 3 Jahre |
| Anders Nykjaer | M | - |
University of Aarhus
| 3 Jahre |
| Morten Brøgger | M | 55 |
University of Aarhus
| 1 Jahre |
| Guðmundur Ólason | M | 52 |
University of Aarhus
| 1 Jahre |
| Flemming Besenbacher | M | 71 |
University of Aarhus
| 3 Jahre |
| Asmus Rotne | M | 50 |
University of Aarhus
| 4 Jahre |
| Hans-Peter Torsten Ekre | M | 74 |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
| Morten Kierkegaard | M | 54 |
University of Aarhus
| 1 Jahre |
| Steffen B. Petersen | M | - |
University of Aarhus
| 5 Jahre |
| Eskil Söderlind | M | 65 |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
| Niels Hobolt | M | - |
University of Aarhus
| 1 Jahre |
| Henrijette Richter | M | 53 |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
| Jakob Bardram | M | 56 |
University of Aarhus
| 3 Jahre |
| Jørn Frederik Falch | M | - |
Cytoguide ApS
Cytoguide ApS Pharmaceuticals: MajorHealth Technology Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases. | - |
| Søren Steen Pedersen | M | - |
University of Aarhus
| 2 Jahre |
| Henriette Schütze | F | 56 |
University of Aarhus
| 1 Jahre |
| Henrik Poulsen | M | 57 |
University of Aarhus
| 1 Jahre |
| Truls Kristian Hauger | M | 52 |
University of Aarhus
| 2 Jahre |
| John Sommer Schmidt | M | 51 |
University of Aarhus
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Dänemark | 55 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Holger Jon Møller
- Persönliches Netzwerk
